Zobrazeno 1 - 10
of 377
pro vyhledávání: '"Lymph node negative"'
Publikováno v:
Frontiers in Endocrinology, Vol 15 (2024)
BackgroundIt remains unclear which category of patients with clinically lymph node negative (cN0) papillary thyroid carcinoma (PTC) might have higher risk of occult lateral lymph node metastasis (OLLNM) due to the conflicting results in previous stud
Externí odkaz:
https://doaj.org/article/f7155677b70d4c3b948f8e5ba02268db
Autor:
Ines Block, Mark Burton, Kristina P. Sørensen, Martin J. Larsen, Thi T. N. Do, Martin Bak, Søren Cold, Mads Thomassen, Qihua Tan, Torben A. Kruse
Publikováno v:
Cancer Medicine, Vol 13, Iss 9, Pp n/a-n/a (2024)
Abstract Background Current clinical markers overestimate the recurrence risk in many lymph node negative (LNN) breast cancer (BC) patients such that a majority of these low‐risk patients unnecessarily receive systemic treatments. We tested if diff
Externí odkaz:
https://doaj.org/article/f87c4fa2f826470a8dde22579f310ce2
Publikováno v:
Frontiers in Endocrinology, Vol 14 (2024)
ObjectiveThis study aimed to develop and apply a prediction model to estimate the probability of lateral lymph node metastasis (LLNM) in patients with cN0 unilateral papillary thyroid carcinoma (PTC) with central lymph node metastasis (CLNM).SettingA
Externí odkaz:
https://doaj.org/article/175fd22e5dec46ef8a3f66a4a3916a82
Autor:
Linjun Wang, Yiwen Xia, Tianlu Jiang, Ying Li, Yikai Shen, Jie Lin, Fengyuan Li, Weizhi Wang, Diancai Zhang, Hao Xu, Li Yang, Zekuan Xu
Publikováno v:
Journal of Investigative Surgery, Vol 36, Iss 1 (2023)
Background The prognostic significance of neural invasion (NI) in gastric cancer (GC) has not been established. This study is to investigate the characteristic and prognostic value of NI in GC. Methods 592 patients who had undergone gastrectomy for G
Externí odkaz:
https://doaj.org/article/21e7f312ba8d46a18e822a52296ee81d
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Kaiwen Shen, Longdi Yao, Jingyuan Zhu, Ximing Gu, Jie Wang, Wei Qian, Zhijian Zheng, Deyuan Fu, Song Wu
Publikováno v:
BMC Cancer, Vol 22, Iss 1, Pp 1-15 (2022)
Abstract Background There is no clear consensus on the benefits of adjuvant chemotherapy for tumor-node-metastasis (TNM) stage T1 (T1N0M0) breast cancer (BC). Our study investigated the effects of adjuvant chemotherapy on T1N0M0 BC patients. Methods
Externí odkaz:
https://doaj.org/article/c77486db002843cd86e1f34909a7a325
Autor:
Çağlar Ünal, Tolga Özmen, Çetin Ordu, Kezban Nur Pilanci, Ahmet Serkan İlgün, Erhan Gökmen, Elvina Almuradova, Mustafa Özdoğan, Nilüfer Güler, Cihan Uras, Halil Kara, Orhan Demircan, Selver Işık, Gül Alço, Pınar Saip, Esra Aydın, Tomris Duymaz, Filiz Çelebi, Kanay Yararbaş, Gursel Soybir, Vahit Ozmen
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
BackgroundThe Oncotype Dx recurrence score (ODx-RS) guides the adjuvant chemotherapy decision-making process for patients with early-stage hormone receptor-positive, HER-2 receptor-negative breast cancer. This study aimed to evaluate survival and its
Externí odkaz:
https://doaj.org/article/a5aa0615c47b4b81b959ce30fea9d08c
Publikováno v:
Breast, Vol 60, Iss , Pp 1-5 (2021)
Background: The prognostic impact of postmastectomy radiation therapy (PMRT) on high-risk patients with T1-2N0 breast cancer is controversial. We aimed to investigate the effect of PMRT on high-risk patients with T1-2N0 breast cancer. Methods: A tota
Externí odkaz:
https://doaj.org/article/b860bf5e59964c3d896f36d81a8a6ee7
Publikováno v:
Pharmacogenomics and Personalized Medicine, Vol Volume 14, Pp 1701-1713 (2021)
Yao Li,1,* Xin Yang,1,* Jie Sun,2 Yangyang Zhao,3 Qi Zhou,3 Bin Hua1 1Breast Center, Department of Thyroid-Breast-Hernia Surgery, Department of General Surgery, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine
Externí odkaz:
https://doaj.org/article/fa8e627ab44646a3a0e8cd7f55b60ec9
Publikováno v:
Current Oncology, Vol 28, Iss 2, Pp 1137-1142 (2021)
Uncertainty exists around the need to include an anthracycline if taxane-based adjuvant chemotherapy is being used for human epidermal growth factor receptor-2 (HER2) negative and axillary lymph node negative (LNN) breast cancer. We identified all pa
Externí odkaz:
https://doaj.org/article/187d0c22de6044488ca75212119e383b